Condition: Advanced/Metastatic Non-Small Cell Lung Cancer · Sponsor: Regeneron Pharmaceuticals
This study will evaluate two study drugs called ubamatamab and REGN7075, to see if they can help treat advanced or metastatic Non-Small Cell Lung Cancer (NSCLC), and sarilumab, to evaluate to see if it can help with immune-related side effects from ubamatamab. The study is looking at: * How well ubamatamab and REGN7075 works * The side effects that ubamatamab and REGN7075 might cause * How much ubamatamab and REGN7075 is in the blood at different times * If the body makes antibodies to ubamatamab and/or REGN7075, this may cause the ubamatamab to not work as well
This description comes directly from the study's public registry record.
Clinical Trials Administrator · 844-734-6643 · clinicaltrials@regeneron.com
Always discuss trial participation with your own doctor first.
| Cancer Treatment Centers of America, Phoenix | Goodyear, Arizona, United States | Recruiting |
| The City of Hope Orange County Lennar Foundation Cancer Center | Irvine, California, United States | Recruiting |
| Rush University Medical Center | Chicago, Illinois, United States | Recruiting |
| University of Illinois Chicago | Chicago, Illinois, United States | Recruiting |
| Franciscan Health | Munster, Indiana, United States | Recruiting |
| University of Maryland Greenebaum Comprehensive Cancer Center | Baltimore, Maryland, United States | Recruiting |
| Washington University School of Medicine | St Louis, Missouri, United States | Recruiting |
| University of Tennessee Medical Center | Knoxville, Tennessee, United States | Recruiting |
| Sarah Cannon Research Institute | Nashville, Tennessee, United States | Recruiting |
| University of Texas Medical Branch | Galveston, Texas, United States | Recruiting |
| The University of Texas MD Anderson Cancer Center | Houston, Texas, United States | Recruiting |
| Baylor Scott & White Health | Temple, Texas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07154290